NG
VRTX icon

NWK Group’s Vertex Pharmaceuticals VRTX Stock Holding History

NWK Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,903
Closed -$5.07M – 78
2024
Q3 		$5.07M Sell
10,903
-84
-0.8% -$40.4K 2.06% 21
2024
Q2 		$5.15M Hold
10,987
– – 2.16% 19
2024
Q1 		$4.59M Buy
+10,987
New +$4.64M 2.15% 19
2021
Q1 		– Sell
-9
Closed -$2K – 217
2020
Q4 		$2K Sell
9
-11,231
-100% -$2.58M ﹤0.01% 198
2020
Q3 		$3.06M Buy
11,240
+271
+2% +$74.8K 1.51% 24
2020
Q2 		$3.18M Buy
10,969
+335
+3% +$90.8K 1.81% 20
2020
Q1 		$2.53M Buy
+10,634
New +$2.44M 2.16% 20

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

NWK Group's VRTX Position: Q4 2024 in Review

NWK Group sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 10,903 shares — an estimated $5.07M sold.

NWK Group first reported a position in VRTX in Q1 2020 and held it in 7 quarters. The position peaked at $5.15M in Q2 2024. 1,557 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • NWK Group reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • NWK Group sold 10,903 Vertex Pharmaceuticals shares in Q4 2024, an estimated $5.07M.
  • NWK Group first reported a position in Vertex Pharmaceuticals in Q1 2020 and held it in 7 quarters.
  • NWK Group's Vertex Pharmaceuticals position peaked at $5.15M in Q2 2024.
  • 1,557 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on NWK Group's 13F filing for Q4 2024, filed 13 Feb 2025.